Literature DB >> 21435117

Deep venous thrombosis screening in patients with inherited bleeding disorders and central venous catheters.

C R Cost1, J M Journeycake.   

Abstract

Children with inherited bleeding disorders often require central venous catheters (CVCs). Although CVCs are known to be complicated by deep venous thrombosis (DVT), little is known about the timeline of DVT development or risk of post-thrombotic syndrome (PTS). The aim of this study was to determine the timeline and confirm the incidence of thrombosis in patients with bleeding disorders who have CVCs. In 2002, we instituted a screening programme to monitor for CVC-related complications in children with haemophilia and von Willebrand disease. This is a retrospective review of this cohort. All children with CVC followed up between 1 January 2000 and 1 June 2009 were evaluated for DVT every 24 months with contrast venography and Doppler sonography. An institutional PTS severity scale was utilized at each visit. Thirty-six patients had 37 CVCs placed. Thirty patients had imaging studies, with DVT observed in 14 (47%). Most cases of DVT were diagnosed at the first venogram (median CVC duration 26 months). There were no abnormal ultrasound results. Sixteen patients (44%) had clinical findings consistent with PTS, including 10 (71%) with an abnormal venogram. Dilated chest wall veins appeared to be more strongly associated with underlying DVT (positive predictive value of 0.8) than arm circumference discrepancy. Successful transition to use of peripheral veins occurred at a median of 11 months after abnormal venograms. CVC-related DVT is common in children with inherited bleeding disorders and likely occurs earlier than previously thought. Clinical signs of PTS are also common, but long-term sequelae and severity of PTS are not known.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21435117      PMCID: PMC4134000          DOI: 10.1111/j.1365-2516.2011.02515.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  12 in total

1.  A cross-sectional study evaluating post-thrombotic syndrome in children.

Authors:  Stefan Kuhle; Barbara Koloshuk; Velma Marzinotto; Mary Bauman; Patricia Massicotte; Maureen Andrew; A Chan; Mohamed Abdolell; Lesley Mitchell
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

2.  Retrospective comparative examination of the long term effects of venous access devices on upper extremity limb measurement in children with haemophilia: pilot observations from a single haemophilia treatment centre.

Authors:  B A Christie; K Baumann; M H Kurth
Journal:  Haemophilia       Date:  2006-09       Impact factor: 4.287

3.  Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports.

Authors:  J Ingram; S Weitzman; M L Greenberg; P Parkin; R Filler
Journal:  Am J Pediatr Hematol Oncol       Date:  1991

Review 4.  Post-thrombotic syndrome.

Authors:  C Barnes; F Newall; P Monagle
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

5.  Catheter-related deep venous thrombosis in children with hemophilia.

Authors:  J M Journeycake; C T Quinn; K L Miller; J L Zajac; G R Buchanan
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 6.  Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.

Authors:  P Komvilaisak; B Connolly; A Naqvi; V Blanchette
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

Review 7.  Diagnosis of venous thromboembolism in children.

Authors:  Christoph Male; Stefan Kuhle; Lesley Mitchell
Journal:  Semin Thromb Hemost       Date:  2003-08       Impact factor: 4.180

8.  Complications of central venous access devices in paediatric haemophilia patients.

Authors:  J A Domm; M G Hudson; R L Janco
Journal:  Haemophilia       Date:  2003-01       Impact factor: 4.287

Review 9.  Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.

Authors:  C E Neunert; K L Miller; J M Journeycake; G R Buchanan
Journal:  Haemophilia       Date:  2007-12-28       Impact factor: 4.287

10.  Fatal central venous catheter-related infection in haemophilia.

Authors:  S E Crary; G R Buchanan; J M Journeycake
Journal:  Haemophilia       Date:  2006-03       Impact factor: 4.287

View more
  5 in total

1.  Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: A systematic review.

Authors:  Anjali A Sharathkumar; Tina Biss; Ketan Kulkarni; Sanjay Ahuja; Matt Regan; Christoph Male; Shoshana Revel-Vilk
Journal:  J Thromb Haemost       Date:  2020-04-15       Impact factor: 5.824

Review 2.  Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.

Authors:  E Vidal; A Sharathkumar; J Glover; E V S Faustino
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 3.  Venous Thromboembolism in Children with Cancer and Blood Disorders.

Authors:  Richard H Ko; Courtney D Thornburg
Journal:  Front Pediatr       Date:  2017-02-06       Impact factor: 3.418

4.  Fibers Generated by Plasma Des-AA Fibrin Monomers and Protofibril/Fibrinogen Clusters Bind Platelets: Clinical and Nonclinical Implications.

Authors:  Dennis K Galanakis; Anna Protopopova; Liudi Zhang; Kao Li; Clement Marmorat; Tomas Scheiner; Jaseung Koo; Anne G Savitt; Miriam Rafailovich; John Weisel
Journal:  TH Open       Date:  2021-07-06

5.  Novel characteristics of soluble fibrin: hypercoagulability and acceleration of blood sedimentation rate mediated by its generation of erythrocyte-linked fibers.

Authors:  Dennis K Galanakis; Anna Protopopova; Kao Li; Yingjie Yu; Tahmeena Ahmed; Lisa Senzel; Ryan Heslin; Mohamed Gouda; Jaseung Koo; John Weisel; Marilyn Manco-Johnson; Miriam Rafailovich
Journal:  Cell Tissue Res       Date:  2022-03-11       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.